Drugs / GLA-AF
GLA-AF
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03110757 | May 2018 → Nov 2019 | intestinal schistosomiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02476773 | Jan 2016 → Jun 2017 | hookworm infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02337855 | Feb 2015 → Jan 2017 | intestinal schistosomiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01717950 | Sep 2013 → Jun 2015 | hookworm infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01657929 | Sep 2012 → Jan 2014 | avian influenza | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT01385189 | May 2012 → Jan 2015 | hookworm infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03172975 | Mar 2018 → Dec 2024 | hookworm infectious disease | Baylor College of Medicine | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01966900 Comparator | Oct 2013 → Nov 2015 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 1 | NCT01922284 Background | Jun 2013 → Jan 2014 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLA-AF | “GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity.” NCT01717950 ↗ |
| Known as | Gluco-pyranosylphospho-lipid A aqueous formulation | “Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist” NCT03110757 ↗ |
| Known as | glucopyranosyl lipid adjuvant - aqueous formulation | “the adjuvant is glucopyranosyl lipid adjuvant - aqueous formulation (GLA-AF).” NCT01966900 ↗ |
| Known as | Glucopyranosyl-Lipid A | “an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)” NCT03172975 ↗ |
| Action | Activate | “GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity.” NCT01717950 ↗ |
| Modality | Other / unclassified | “5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant” NCT01922284 ↗ |
| Route | Intramuscular | “Vaccinations were administered via intramuscular injection on days 0, 56, and 112.” PMID 28464026 ↗ May 2017 |